Interview with Dominique Amory, President, Lilly France
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Address: 24 Boulevard Vital Bouhot
CS 50004
92521 Neuilly-sur-Seine Cedex
Tel: 01 55 49 34 34
Web: http://www.lilly.com/Pages/home.aspx
The Pharmaceutical company Lilly has been in France since 1962. This is the 4th subsidiary of Lilly after the United States, Japan and Germany.
Lilly France is the 16th French pharmaceutical company and has a turnover of 2.3 billion euros in 2008, including 1.6 billion under its manufacturing (factory Fegersheim).
Advancing medicine, contributing to major therapeutic advances, allowing everyone to live better and longer: this is the mission of the pharmaceutical company Lilly.
Eli Lilly and Company is a specialty pharmaceutical company entirely focused on innovation and committed to developing a portfolio of drugs to both the best and the first in their class, to allow patients to be healthier and live a longer and more active.
To do this, we use the results of recent medical studies in our laboratories pharmaceutical world. We are collaborating with eminent scientific organizations, and we appeal to the most advanced technological tools, while ensuring the high quality service to our customers.
Through internal programs and external initiatives, we intend to meet the most urgent medical needs. Lilly employs more than 40 450 people worldwide and markets its medicines in 143 countries. The company has major research and development centers in 9 countries and conducts clinical trials in over 50 countries.
Lilly’s drugs treat depression, schizophrenia, cancer, diabetes, osteoporosis and other disorders.
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
See our Cookie Privacy Policy Here
